Published in Monoclonal Antibodies Weekly, February 2nd, 2000
"Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa," wrote C. J. Dunn and colleagues of Adis International Ltd, New Zealand. "The drug is used in conjunction with heparin and aspirin to prevent ischemic complications associated with percutaneous coronary revascularization in patients with coronary heart disease."
Dunn et al. published their study in Pharmacoeconomics ("Abciximab - a pharmacoeconomic review of its use in percutaneous coronary revascularization,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Monoclonal Antibodies Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.